Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review
Why tumors grow back inside the radiation beam, not just at the edges
This retrospective single-center review of 41 patients with high-grade glioma found that central recurrence was the most common pattern (36.…
New data shows brain tumors often return in the middle of the radiation zone, suggesting biology, not just targeting errors, drives failure.
GSC-associated gene signature predicts survival in adult and pediatric high-grade glioma patients.
New Brain Tumor Test Predicts Survival More Accurately
This cohort study evaluated a GSC-associated gene signature involving the FAM86B1/FAM86B2 axis in adult and pediatric high-grade glioma pati…
A new model uses specific genes to predict how long patients might live with aggressive brain tumors.
Review of STING agonists for high-grade and diffuse midline glioma discusses systemic toxicity and delivery constraints.
New Brain Drug Target Could Wake Up the Immune System
This narrative review examines the potential of STING agonists, cyclic dinucleotides, and related compounds for treating high-grade glioma a…
A new brain drug target aims to wake up the immune system's defenses against dangerous, hard-to-treat tumors that hide from the body's natur…
Locoregional CAR T-cell delivery reduces severe adverse events in high-grade glioma patients
Could a new way to deliver brain cancer therapy make it safer and more effective?
A meta-analysis of 14 clinical trials involving 194 high-grade glioma patients found locoregional CAR T-cell delivery was associated with re…
Delivering brain cancer therapy directly to the tumor instead of through the bloodstream cuts severe side effects by more than 60% and shows…